SG Americas Securities
GALT icon

SG Americas Securities’s Galectin Therapeutics GALT Stock Holding History

SG Americas Securities’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13,935
Closed -$18K – 3567
2024
Q4 		$18K Buy
+13,935
New +$33.4K ﹤0.01% 3017
2020
Q3 		– Sell
-20,418
Closed -$62K – 2969
2020
Q2 		$62K Buy
20,418
+7,542
+59% +$19K ﹤0.01% 3500
2020
Q1 		$25K Buy
+12,876
New +$31.3K ﹤0.01% 3279
2014
Q3 		– Sell
-24,744
Closed -$342K – 2708
2014
Q2 		$342K Buy
+24,744
New +$308K ﹤0.01% 1821

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

SG Americas Securities's GALT Position: Q1 2025 in Review

SG Americas Securities sold out of Galectin Therapeutics (GALT) in Q1 2025, closing a stake of 13,935 shares — an estimated $18K sold.

SG Americas Securities first reported a position in GALT in Q2 2014 and held it in 4 quarters. The position peaked at $342K in Q2 2014. 93 funds tracked by Wall St. Rank hold GALT as of Q1 2025.

  • SG Americas Securities reported no remaining Galectin Therapeutics position as of Q1 2025 after selling out during the quarter.
  • SG Americas Securities sold 13,935 Galectin Therapeutics shares in Q1 2025, an estimated $18K.
  • SG Americas Securities first reported a position in Galectin Therapeutics in Q2 2014 and held it in 4 quarters.
  • SG Americas Securities's Galectin Therapeutics position peaked at $342K in Q2 2014.
  • 93 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2025.

Based on SG Americas Securities's 13F filing for Q1 2025, filed 15 Apr 2025.